Bruno Leroy

1.1k total citations
27 papers, 791 citations indexed

About

Bruno Leroy is a scholar working on Epidemiology, Microbiology and Otorhinolaryngology. According to data from OpenAlex, Bruno Leroy has authored 27 papers receiving a total of 791 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Epidemiology, 6 papers in Microbiology and 5 papers in Otorhinolaryngology. Recurrent topics in Bruno Leroy's work include Pneumonia and Respiratory Infections (15 papers), Pneumocystis jirovecii pneumonia detection and treatment (5 papers) and Antibiotics Pharmacokinetics and Efficacy (5 papers). Bruno Leroy is often cited by papers focused on Pneumonia and Respiratory Infections (15 papers), Pneumocystis jirovecii pneumonia detection and treatment (5 papers) and Antibiotics Pharmacokinetics and Efficacy (5 papers). Bruno Leroy collaborates with scholars based in United States, France and Sweden. Bruno Leroy's co-authors include Martine Muffat‐Joly, Thierry Gilbert, Manickam Rangaraju, Guy Tellier, Kees-Peter de Roos, E. Ruuth, Vijay O. Bhargava, Arturo Fraile Torres, Jun Yi Shi and Lars Hagberg and has published in prestigious journals such as Journal of Antimicrobial Chemotherapy, Atherosclerosis and Clinical Microbiology and Infection.

In The Last Decade

Bruno Leroy

25 papers receiving 740 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bruno Leroy United States 15 377 267 190 187 126 27 791
Pieter Degraeuwe Netherlands 14 289 0.8× 241 0.9× 59 0.3× 445 2.4× 160 1.3× 40 854
Elisavet Diamanti Greece 16 139 0.4× 231 0.9× 103 0.5× 187 1.0× 33 0.3× 41 690
Alessandro Bulfoni Italy 15 132 0.4× 133 0.5× 218 1.1× 20 0.1× 60 0.5× 59 775
Peter Vervaart Australia 7 71 0.2× 108 0.4× 132 0.7× 172 0.9× 31 0.2× 9 451
Abiodun Adefurin United States 9 67 0.2× 78 0.3× 41 0.2× 20 0.1× 62 0.5× 10 293
Melisa Cooper United Kingdom 12 166 0.4× 28 0.1× 28 0.1× 18 0.1× 270 2.1× 20 583
Dorota Pawlik Poland 15 234 0.6× 173 0.6× 13 0.1× 335 1.8× 18 0.1× 54 722
Revital Greenberg Israel 13 85 0.2× 143 0.5× 42 0.2× 52 0.3× 34 0.3× 20 594
Thilak Priyantha Weerarathna Sri Lanka 11 221 0.6× 30 0.1× 25 0.1× 39 0.2× 16 0.1× 38 788
Carlton K.K. Lee United States 16 117 0.3× 164 0.6× 5 0.0× 166 0.9× 151 1.2× 30 845

Countries citing papers authored by Bruno Leroy

Since Specialization
Citations

This map shows the geographic impact of Bruno Leroy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruno Leroy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruno Leroy more than expected).

Fields of papers citing papers by Bruno Leroy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bruno Leroy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruno Leroy. The network helps show where Bruno Leroy may publish in the future.

Co-authorship network of co-authors of Bruno Leroy

This figure shows the co-authorship network connecting the top 25 collaborators of Bruno Leroy. A scholar is included among the top collaborators of Bruno Leroy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bruno Leroy. Bruno Leroy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yuan, William, Brett K. Beaulieu‐Jones, Richard C. Krolewski, et al.. (2021). Accelerating diagnosis of Parkinson’s disease through risk prediction. BMC Neurology. 21(1). 201–201. 18 indexed citations
2.
3.
4.
Leroy, Bruno, M. Uhart, Pascal Maire, & Laurent Bourguignon. (2012). Evaluation of fluoroquinolone reduced dosage regimens in elderly patients by using pharmacokinetic modelling and Monte Carlo simulations. Journal of Antimicrobial Chemotherapy. 67(9). 2207–2212. 14 indexed citations
5.
Fogarty, Charles, et al.. (2005). Efficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter study. BMC Infectious Diseases. 5(1). 43–43. 13 indexed citations
6.
Roos, Kees-Peter de, et al.. (2005). Bacteriological efficacy of 5-day therapy with telithromycin in acute maxillary sinusitis. International Journal of Antimicrobial Agents. 25(3). 237–246. 2 indexed citations
7.
Shi, Jun Yi, Sunny Chapel, Guy Montay, et al.. (2005). Effect of ketoconazole on the pharmacokinetics and safety of telithromycin and clarithromycin in older subjects with renal impairment. International Journal of Clinical Pharmacology and Therapeutics. 43(3). 123–133. 16 indexed citations
8.
Shi, Jun Yi, Guy Montay, Sunny Chapel, et al.. (2004). Pharmacokinetics and Safety of the Ketolide Telithromycin in Patients with Renal Impairment. The Journal of Clinical Pharmacology. 44(3). 234–244. 32 indexed citations
9.
Norrby, S. Ragnar, et al.. (2004). Evaluation of 5-day therapy with telithromycin, a novel ketolide antibacterial, for the treatment of tonsillopharyngitis. Clinical Microbiology and Infection. 10(7). 615–623. 10 indexed citations
10.
Shi, Jun Yi, Guy Montay, Bruno Leroy, & Vijay O. Bhargava. (2004). Effects of Itraconazole or Grapefruit Juice on the Pharmacokinetics of Telithromycin. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 25(1). 42–51. 17 indexed citations
11.
Roos, Kees-Peter de, et al.. (2004). Clinical and bacteriological efficacy of 5-day telithromycin in acute maxillary sinusitis: a pooled analysis. Journal of Infection. 50(3). 210–220. 16 indexed citations
12.
Carbon, C, et al.. (2003). Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia. Clinical Microbiology and Infection. 9(7). 691–703. 41 indexed citations
13.
Tellier, Guy, et al.. (2003). Efficacy and Tolerability of Telithromycin for 5 or 10 Days vs Amoxicillin/Clavulanic Acid for 10 days in Acute Maxillary Sinusitis. Ear Nose & Throat Journal. 82(8). 576–590. 44 indexed citations
14.
15.
Aubier, Michel, et al.. (2002). Telithromycin is as effective as amoxicillin/clavulanate in acute exacerbations of chronic bronchitis. Respiratory Medicine. 96(11). 862–871. 59 indexed citations
16.
Leroy, Bruno, et al.. (2002). Efficacy and Safety of Telithromycin in Community-acquired Pneumonia. Current Medical Research and Opinion. 18(7). 397–400. 26 indexed citations
17.
Roos, Kees-Peter de, et al.. (2002). Efficacy and Tolerability of Once-Daily Therapy with Telithromycin for 5 or 10 Days for the Treatment of Acute Maxillary Sinusitis. Chemotherapy. 48(2). 100–108. 57 indexed citations
18.
Lannoo, Engelien, Annick De Paepe, Bruno Leroy, & Evert Thiery. (1995). Neuropsychological test performance versus postconcussional complaints after moderate to severe head injury: a two-year follow up. Ghent University Academic Bibliography (Ghent University). 1 indexed citations
19.
Réfabert, L., et al.. (1995). Azathioprine-induced pulmonary haemorrhage in a child after renal transplantation. Pediatric Nephrology. 9(4). 470–473. 5 indexed citations
20.
Leroy, Bruno, et al.. (1988). Estrogen-like effect of 5-androstene-3β, 17β-diol on the induction of fetal thymidine kinase in the rat uterus. Journal of Steroid Biochemistry. 31(4). 453–458. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pieter Degraeuwe Breakdown of academic impact, for papers by Elisavet Diamanti Breakdown of academic impact, for papers by Alessandro Bulfoni Breakdown of academic impact, for papers by Peter Vervaart Breakdown of academic impact, for papers by Abiodun Adefurin Breakdown of academic impact, for papers by Melisa Cooper Breakdown of academic impact, for papers by Dorota Pawlik Breakdown of academic impact, for papers by Revital Greenberg Breakdown of academic impact, for papers by Thilak Priyantha Weerarathna Breakdown of academic impact, for papers by Carlton K.K. Lee
Rankless by CCL
2026